- Home
- JAN
JAN
JanOne Inc. (NV)
as 07-26-2024 4:00pm EST
JanOne Inc is focused on being a clinical-stage pharmaceutical company committed to finding treatments for conditions that cause severe pain and bringing drugs to market with non-addictive pain-relieving properties. One of the Company's goals is to reduce the need for prescriptions for dangerous opioid drugs by treating underlying diseases that cause severe pain. The company operates in two operating segments, namely Biotechnology, and discontinued operations.
| Founded: | 1976 | Country: | United States |
| Employees: | N/A | City: | LAS VEGAS |
| Market Cap: | 30.1M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 148.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.22 - $5.26 | Next Earning Date: | 08-27-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest JanOne Inc. (NV) News
JAN Breaking Stock News: Dive into JAN Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Janus Henderson Group plc (JHG) Reports Next Week: Wall Street Expects Earnings Growth
Zacks
2 days ago
United Rentals (URI) Tops Q2 Earnings Estimates
Zacks
2 days ago
SEI Investments (SEIC) Q2 Earnings Top Estimates
Zacks
2 days ago
Janus Henderson Group plc (JHG) is a Great Momentum Stock: Should You Buy?
Zacks
2 days ago
Is Interactive Brokers (IBKR) Stock Outpacing Its Finance Peers This Year?
Argus Research
3 days ago
JHG: What does Argus have to say about JHG?
Zacks
3 days ago
Top 5 Investment Management Stocks to Enrich Your Portfolio
Business Wire
4 days ago
Janus International Group to Report Second Quarter 2024 Results on August 7, 2024
Compare JAN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JAN JanOne Inc. (NV) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.